Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics-Reference-Cited by-同舟云学术

Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics

Published:2015-04 Issue: Volume:58 Page:1-7
ISSN:0278-5846
Container-title:Progress in Neuro-Psychopharmacology and Biological Psychiatry
language:en
Short-container-title:Progress in Neuro-Psychopharmacology and Biological Psychiatry

Author:

Hargarter Ludger,Cherubin Pierre,Bergmans Paul,Keim Sofia,Rancans Elmars,Bez Yasin,Parellada Eduard,Carpiniello Bernardo,Vidailhet Pierre,Schreiner Andreas

Funder

Janssen Cilag International NV

Publisher

Elsevier BV

Subject

Biological Psychiatry,Pharmacology

Reference46 articles.

1. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected;Agid;Arch Gen Psychiatry,2003

2. Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial;Alphs;Ann Genet Psychiatry,2011

3. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study;Andreasen;Am J Psychiatry,2013

4. Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients;Ascher-Svanum;BMC Psychiatry,2009

5. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease;Atkinson;Health Qual Life Outcomes,2004

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Formulation, Design, Optimization, and Characterization of Novel Long-acting Injectable Dosage Form of Anti-psychotic Drug;Current Drug Therapy;2024-09

2. Characteristics of patients with schizophrenia switching from oral antipsychotics to once-monthly paliperidone palmitate (PP1M): a systematic review;BMC Psychiatry;2024-01-19

3. Effectiveness and Safety of Switching from Oral Antipsychotics to Once-Monthly Paliperidone Palmitate (PP1M) in the Management of Schizophrenia: A Systematic Review and Meta-Analysis;CNS Drugs;2023-07-25

4. Assessing the expression of two post-transcriptional BDNF regulators, TTP and miR-16 in the peripheral blood of patients with Schizophrenia;BMC Psychiatry;2022-12-08

5. Results from PSIPROSPER: A multicenter retrospective study to analyze the impact of treatment with paliperidone palmitate 1-month on clinical outcomes and hospital resource utilization in adult patients with schizophrenia in Portugal;Frontiers in Psychiatry;2022-11-01